EGFR and neoplasm: For two other fourth-generation EGFR inhibitors, JIN-A02 and BBT-176, the successful application in both in vitro and in vivo studies were published: JIN-A02 inhibited ex19del/T790M/C797S and L858R/T790M/C797S EGFR-mutant Ba/F3 cells (IC50 = 51.0 and 49.2 nM, respectively) and resulted in tumor regression in ex19del/T790M/C797S Ba/F3 xenograft mouse models [204].